Shorter Turnaround Time for BRAF Mutation Testing

July 11, 2016

Obtaining blood biopsies instead of invasive tissue biopsies may be less risky for patients, faster, and cost less.

A recent study published in Molecular Cancer Therapeutics and in an American Association of Cancer Research news release suggests that cell-free DNA from plasma provides an easy and obtainable material for BRAF mutation analysis for diagnostics and response monitoring. Obtaining blood biopsies instead of invasive tissue biopsies may be less risky for patients, faster, and cost less.